Immunotherapy in first-line standard therapy significantly improves survival in metastatic or recurrent cervical cancer medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in patients with metastatic, persistent, or recurrent cervical cancer, a phase 3 trial suggests. Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in metastatic, persistent, or recurrent cervical cancer.
Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in patients with metastatic, persistent, or recurrent cervical cancer, a phase 3 trial suggests. Adding atezolizumab to bevacizumab and platinum-based chemotherapy can improve outcomes in metastatic, persistent, or recurrent cervical cancer.
The addition of atezolizumab to bevacizumab and chemotherapy resulted in a significant improvement in progression-free survival and overall survival vs standard treatment with bevacizumab and chemotherapy in patients with metastatic, persistent, or recurrent cervical cancer.